Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer

Launched by CENTRE HENRI BECQUEREL · Dec 9, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of immune checkpoint inhibitors (ICIs) on the blood vessels of patients with head and neck cancer or lung cancer. ICIs are a type of treatment that helps the immune system fight cancer. The goal of this trial is to better understand how these drugs might affect blood vessels, as they are increasingly used in cancer treatment. The trial is currently looking for participants aged 18 and older who have been diagnosed with lung or head and neck cancer and are eligible for ICI treatment based on a team of doctors’ recommendations.

To participate, individuals need to be in good health overall (with a specific health status rating), agree to take part in the study, and not have certain health issues or recent treatments that could interfere with the trial. Participants can expect close monitoring throughout the study to ensure their safety and gather important information about how the treatment works. This trial is important as it aims to enhance our understanding of the benefits and potential side effects of ICIs, ultimately helping to improve cancer treatment for many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed informed consent.
• • Patient over 18 years of age
• • Patient with lung or head and neck cancer who should be treated with ICI as a single agent according to the market indications, decision taken during a multidisciplinary consultation meeting
• • WHO 0 or 1
• • Patient affiliated to or benefiting from a social protection scheme.
• Exclusion Criteria:
• • Indication for combined anti-PD-1 and chemotherapy (for patients with lung cancer)
• • History of radiotherapy treatment
• • History of chemotherapy or targeted therapy within the last 3 weeks
• • Bilateral vascular carotid murmur
• • Absence of sinus rhythm
• • Presence of a pacemaker with permanent electrical stimulation
• • Absence of peripheral carotid and/or femoral pulses on both sides
• • Contraindication to the prescription of an ICI
• • Patient deprived of liberty by an administrative or judicial decision or patient placed under court protection, guardianship or curatorship
• • Pregnant or breastfeeding woman

Trial Officials